Search Results for 'Tysabri'

Athlone-based pharmaceutical company Elan has reported an increase of 24 per cent in revenue over last year’s figures.

Pharmaceutical company Elan has put plans to shed its Athlone division on hold, in spite of indications earlier this year that it was planning to separate the Athlone-based Elan Drug Technologies (EDT) from the rest of the company.

The CEO of Athlone’s biggest private employer, Kelly Martin of Elan, is to step down in 2012, the firm announced this week.

Athlone-based Elan has claimed that a post-hoc analysis showed that its controversial multiple sclerosis drug Tysabri increases the probability of achieving sustained improvement in physical disability over two years when compared to a placebo.

Local TD Denis Naughten has called on the Government to intervene to secure 500 new Elan jobs, following revelations this week that the company plans to eventually sell its Athlone plant.

Two healthcare giants based in the midlands and the west have this week posted first quarter losses — despite a massive increase in sales in both companies.

Athlone-based drug developer and its US partner, Biogen Idec, last evening hailed success from a study into the effects of their MS drug, Tysabri in repairing damage to the myelin sheath, a key cause of MS.

The Monksland-based phamaceutical firm Elan has been summoned to appear in a Federal court in the US after disclosing two cases of a brain disorder related to its trump product, prior to a €605m ($885m) share sale earlier this month.

Athlone-based pharmaceutical company, Elan, and its US partner Biogen have announced that their drug Tysabri has been proven to significantly reduce the rate of hospitalisation of patients with moderate-to-severe Crohn’s disease.